Biomarkers and Pharmaceutical Care

A biomarker response under prescribed therapy reflects drug response. In our view, an unfavourable clinical outcome should be addressed as “treatment failure” whereas “drug resistance” should be restricted to drugs whose efficacy can be evaluated with pharmacological biomarkers.

Drug Resistance & Vitamin B12

We investigated drug resistance to anti-platelet therapies and combined electronic adherence monitoring of all solid oral drugs with biomarker measurements. We were able to rule out non adherence and therefore to assess drug drug interactions, whereas pharmacogenetic tests and assessment of biomarkers allowed the identification of contributing factors when the lack of biomarker response persisted.

We are applying our study design for vitamine B12 substition.

More informations on www.clinicaltrials.gov Identifier NCT01832129 and NCT02111967

Leader: Dr. Philipp N. Walter
PhD student: Corina Metaxas (since 2013)